Genmab, GSK ofatumumab deal

Genmab (CSE:GEN) granted GlaxoSmithKline (LSE:GSK; GSK) co-development and commercialization rights to ofatumumab ( HuMax-CD20). The human antibody against CD20 is in Phase

Read the full 229 word article

How to gain access

Continue reading with a
two-week free trial.